ALLOSTERIS
LIVE

Serial Number

98895371

Owner

VIB VZW

Attorney

Clifford D. Hyra

Filing Date

Dec 10, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ALLOSTERIS Trademark

Serial Number: 98895371

ALLOSTERIS is a trademark filed by VIB VZW on December 10, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

VIB VZW (8 trademarks)

Suzanne Tassierstraat 1
Gent 9052 , BE

Entity Type: 99

Trademark Details

Filing Date

December 10, 2024

Registration Date

Not Registered

Published for Opposition

September 16, 2025

Goods & Services

Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, autoimmune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical research laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; pharmaceutical drug development services; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research

(Based on 44(e) Priority Application) Pharmaceutical preparations and substances, namely, pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Pharmaceutical preparations and substances, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; (Based on Intent To Use); Medical preparations and substances, namely, fungal preparations in the nature of fungal medications for medical purposes, probiotic preparations for medical use, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Veterinary preparations in the nature of veterinary pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Biologicals preparations for pharmaceutical, medical and veterinary use, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes, namely, diagnostic preparations for veterinary and medical use, pharmaceutical preparations and biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Preparations and substances for use in drug discovery, namely, preparations for growing cells or for producing biologicals for medical, pharmaceutical, and veterinary purposes, and reagents and media for medical, pharmaceutical and veterinary diagnostic purposes, namely, media and reagents serving as inoculate, clinical medical reagents, and diagnostic reagents

Filing History

TEAS PETITION TO AMEND BASIS RECEIVED
Apr 27, 2026 TPAD
SOU TEAS EXTENSION RECEIVED
Apr 27, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 18, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 18, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 18, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 18, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 18, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 15, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 3, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 3, 2025 CNRT
ASSIGNED TO EXAMINER
May 29, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2025 NWOS
NEW APPLICATION ENTERED
Dec 10, 2024 NWAP